000043566 001__ 43566
000043566 005__ 20240823151901.0
000043566 0247_ $$2doi$$a10.6083/bpxhc43566
000043566 037__ $$aIR
000043566 041__ $$aeng
000043566 245__ $$aDistinct inflammatory mechanisms underlie lichen planus and lichenoid reactions to checkpoint inhibition
000043566 260__ $$bOregon Health and Science University
000043566 269__ $$a2024
000043566 336__ $$aAbstract
000043566 520__ $$aCancer treatment has advanced rapidly in the past decade, with checkpoint inhibitors (CPIs) delivering improved outcomes across a variety of malignant indications. However, their application is associated with the development of immune-related adverse events (irAEs), which are linked to the physiological role of checkpoint molecules like PD-1 and CTLA-4 in regulating immunological self-tolerance and safeguarding non-malignant tissues from the immune response. CPIs disrupt these checkpoints, restoring the immune system's cytotoxic function to recognize and eliminate cancer cells, potentially leading to immune dysregulation and the onset of irAEs.
000043566 540__ $$fCC BY
000043566 542__ $$fIn copyright - joint owners
000043566 650__ $$aDermatology$$017631
000043566 650__ $$aMelanoma$$021989
000043566 650__ $$aNeoadjuvant Therapy$$032350
000043566 6531_ $$atranscriptomics
000043566 6531_ $$aimmune-related adverse reaction
000043566 691__ $$aSchool of Medicine$$041369
000043566 692__ $$aDepartment of Dermatology$$041406
000043566 7001_ $$aBillo, Avery$$uOregon Health and Science University$$041354
000043566 7001_ $$aHornick, Noah$$uOregon Health and Science University$$041354
000043566 7001_ $$aFey, Rosalyn M.$$uOregon Health and Science University$$041354
000043566 711__ $$aResearch Week$$uOregon Health and Science University$$d2024
000043566 8564_ $$9f02f8993-fd95-47b3-9002-b3e7663cfd69$$s184681$$uhttps://digitalcollections.ohsu.edu/record/43566/files/ResearchWeek.2024.Billo.Avery.pdf
000043566 980__ $$aResearch Week